1. Home
  2. ECBK vs IPHA Comparison

ECBK vs IPHA Comparison

Compare ECBK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$20.91

Market Cap

182.5M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.57

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECBK
IPHA
Founded
1919
1999
Country
United States
France
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
165.3M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
ECBK
IPHA
Price
$20.91
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
7.6K
★ 32.9K
Earning Date
11-03-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 95.83
N/A
EPS
★ 0.77
N/A
Revenue
★ $598,000.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
$26.07
★ N/A
Revenue Growth
★ 3.64
N/A
52 Week Low
$15.20
$1.17
52 Week High
$21.78
$2.71

Technical Indicators

Market Signals
Indicator
ECBK
IPHA
Relative Strength Index (RSI) 56.20 41.16
Support Level $20.03 $1.36
Resistance Level $21.53 $1.57
Average True Range (ATR) 0.56 0.09
MACD -0.00 0.02
Stochastic Oscillator 76.46 32.14

Price Performance

Historical Comparison
ECBK
IPHA

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: